This article presents the results of diagnostic aspects and planning of surgical treatment of patients with fractures of the zygomatic-orbital complex. Despite the large number of works devoted to this topic, the literature data concerning the choice of diagnostic methods and planning of surgical treatment are rather fragmentary and not systematized, which in turn allows us to focus activities and research on the development and modernization of methods for diagnosing and surgical treatment of fractures of the zygomatic-orbital complex. In this study, the features of fractures of the zygomatic-orbital complex in 117 patients were studied using modern radiological diagnostic methods. The results of our studies showed that the prevalence of isolated damage to the lower wall of the orbit is 29.3%.
1 July 2021 in Advances in Oral and Maxillofacial Surgery
It is known to all, that Covid-19 has spread around the world in the last 1.5 years and has become a medical, economic and social problem 1. The occurrence of complications is increasing as the incidence of the infection increases. In Uzbekistan, many patients with this disease have severe complications such as maxillofacial defects and osteomyelitis within 6–8 months of the end of the acute infectious period, forcing patients to undergo long-term treatment. In the clinical case described in the article, osteomyelitis of the maxillofacial bone was observed in a patient with Covid-19 disease. The process was protracted, there were low signs of acute inflammation, the earliest period of sequestration was 6–8 months, the process continued after sequestration at the margins of the healthy bone. In many cases, the ineffectiveness of treatment due to co-morbidities (diabetes, arterial hypertension), microcirculatory, metabolic, immune and other disorders in the patient, the long course of the process is observed.
11 September 2021 in Advances in Oral and Maxillofacial Surgery
The novel coronavirus spread worldwide in 2020, causing millions of deaths and disabilities. Even though the virus was considered a respiratory virus, its adverse effects can be detected in several body systems. The article describes COVID-19 disease and its complications in the maxillofacial area. Several complications develop either in response to therapeutic modalities used to treat the underlying disease, or due to overuse of particular medications namely glucocorticoids, antirheumatic agents, interleukin 6-inhibitors, and antibiotics. This article will describe a number of complications ranging from mild complications to severe ones such as osteonecrosis of the upper jaw and facial bones, ophthalmologic and neurological complications. It will also summarize recommendations that will help prevent or minimize these complications.
Background: A heavy burden of cranio-maxillofacial complications may be encountered in corona virus disease-2019 patients due to the associated coagulopathy and inflammatory consequences of the disease. This study aims to describe clinical and radiographic features of these complications in 256 patients who developed 1 or more of the following complications: cavernous sinus thrombosis, osteomyelitis or necrosis of the jaws. Methods: Clinical assessment of cranial nerve function and general clinical assessment were performed. Imaging techniques used were multi-slice computed tomography, magnetic resonance imaging, and MRI with contrast enhancement. Results: Thromboembolism of brain and facial blood vessels were associated with inflammation and necrosis. Multi-slice computed tomography/MR angiography showed thrombotic occlusions of the internal carotid artery in the area of the cavernous sinus, and in the ophthalmic veins. Cavernous sinus thrombosis was attributed to coagulopathy and, inflammation of the paranasal sinuses, especially sphenoiditis. A noticeable increase in the size of the cavernous sinus was detected. Compression of the cranial nerves in the cavernous sinus (CS) region causes dysfunction and pathology in the corresponding regions.
Background: Gout is a chronic metabolic disorder frequently complicated by thrombotic events. Genetic variants in hemostasis-related genes may contribute to individual susceptibility to thrombosis in gout patients. Objective: To assess the association between polymorphisms in hemostasis genes and thrombotic risk in patients with gout. Methods: A case–control study was conducted involving 83 patients with gout and 41 healthy controls. Genomic DNA was extracted from peripheral blood leukocytes. Polymorphisms in MTHFR (C677T), F2 (G20210A), F5 (G1691A), and PAI-1 (675 4G/5G) genes were analyzed using multiplex TaqMan real-time PCR. Results: Significant differences were observed for MTHFR C677T and PAI-1 4G/5G polymorphisms. The MTHFR CC and PAI-1 4G/4G genotypes were more frequent in the gout group, potentially indicating increased thrombotic risk. In contrast, the MTHFR CT and PAI-1 5G/5G genotypes were more common in controls. No statistically significant associations were found for F2 and F5 variants. Conclusion: Our findings suggest that MTHFR C677T and PAI-1 4G/5G polymorphisms may contribute to thrombotic predisposition in patients with gout. These results underscore the need for further research to clarify the clinical relevance of these variants in thrombosis risk stratification.